Dosage for Intramuscular Testosterone Undecanoate in Adult Male Hypogonadism
The recommended dosing regimen for intramuscular testosterone undecanoate is 750 mg (3 mL) injected deeply into the gluteal muscle at initiation, at 4 weeks, and then every 10 weeks thereafter as maintenance therapy. 1
Initial Dosing Protocol
- Loading phase: Administer 750 mg intramuscularly at baseline (week 0) and again at week 4 1
- Maintenance phase: Continue with 750 mg every 10 weeks following the second injection 1
- This regimen achieves serum testosterone levels within the normal range (300-1,000 ng/dL) in approximately 94% of patients during the 70-day dosing interval 2
Alternative Dosing Considerations
While the FDA-approved regimen uses 10-week intervals, clinical evidence suggests flexibility in maintenance dosing:
- 1000 mg formulation: Some studies have used 1000 mg at 12-week intervals after appropriate loading doses, which maintains stable trough testosterone levels (14.9-16.5 nmol/L) 3, 4
- More frequent dosing: An 8-week maintenance interval may benefit patients experiencing end-of-interval symptoms, with pharmacokinetic modeling showing an 11% increase in average testosterone concentration and approximately 10% more patients maintaining trough levels >300 ng/dL 5
- Individual optimization: Approximately 66% of patients remain on standard 10-14 week intervals, while 34% may require dose or interval adjustments 4
Mandatory Safety Monitoring
Critical post-injection observation: Patients must be observed in the healthcare setting for 30 minutes following each injection to monitor for pulmonary oil microembolism (POME) and anaphylaxis, which can occur after any injection including the first dose 1
Key Monitoring Parameters
- Hematocrit: Monitor for increases; treatment adjustment required if hematocrit exceeds 54% 6, 1
- PSA levels: Check for significant increases; mean PSA rose from 1.0 to 1.5 ng/mL over 84 weeks in clinical trials 1
- Initial follow-up: Evaluate at 3 months when sexual symptoms typically improve 6
- Ongoing monitoring: Reassess symptoms within 12 months and periodically thereafter, discontinuing therapy if no improvement in sexual function occurs 6
Formulation Preference
Intramuscular formulations are preferred over transdermal preparations when initiating testosterone therapy, as they provide comparable clinical effectiveness and safety with considerably lower costs 6
Important Clinical Caveats
- Diagnostic confirmation required: Ensure diagnosis of hypogonadism with serum testosterone measured on at least two separate mornings, with concentrations below 300 ng/dL 1, 7
- Contraindication for fertility: Testosterone therapy is absolutely contraindicated in men actively seeking fertility; gonadotropin therapy should be used instead for secondary hypogonadism 6
- POME risk: Serious reactions involving cough, dyspnea, chest pain, and syncope have been reported during or immediately after injection, with some requiring emergency care 1
- Appropriate indications: The American College of Physicians recommends testosterone therapy only for sexual dysfunction in hypogonadal men, not for energy, vitality, physical function, or cognition 6